PROBIOTIX HEALTH LS-05 (X90) - Total Liabilities
Based on the latest financial reports, PROBIOTIX HEALTH LS-05 (X90) has total liabilities worth €591.00K EUR (≈ $690.94K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See X90 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
PROBIOTIX HEALTH LS-05 - Total Liabilities Trend (2022–2024)
This chart illustrates how PROBIOTIX HEALTH LS-05's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of PROBIOTIX HEALTH LS-05.
PROBIOTIX HEALTH LS-05 Competitors by Total Liabilities
The table below lists competitors of PROBIOTIX HEALTH LS-05 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Unicasa Indústria de Móveis S.A
SA:UCAS3
|
Brazil | R$200.59 Million |
|
LL Lucky Games publ AB
ST:LADYLU
|
Sweden | Skr35.38 Million |
|
Romios Gold Resources Inc.
V:RG
|
Canada | CA$434.19K |
|
Leader Steel Holdings Bhd
KLSE:9881
|
Malaysia | RM103.11 Million |
|
Brightline Interactive, Inc.
NASDAQ:BTLN
|
USA | $1.05 Million |
|
Brag House Holdings, Inc. Common Stock
NASDAQ:TBH
|
USA | $11.35 Million |
|
TEAM PLC
F:1WQ
|
Germany | €5.29 Million |
|
Atomos Ltd
AU:AMS
|
Australia | AU$23.98 Million |
Liability Composition Analysis (2022–2024)
This chart breaks down PROBIOTIX HEALTH LS-05's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See X90 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PROBIOTIX HEALTH LS-05's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PROBIOTIX HEALTH LS-05 (2022–2024)
The table below shows the annual total liabilities of PROBIOTIX HEALTH LS-05 from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €254.00K ≈ $296.95K |
-60.37% |
| 2023-12-31 | €641.00K ≈ $749.40K |
+82.67% |
| 2022-12-31 | €350.91K ≈ $410.25K |
-- |
About PROBIOTIX HEALTH LS-05
ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. The company offers YourBiotixMH for menopause health; YourBiotixCH InstaMelt and YourBiotixCH for cholesterol maintenance; and YourBiotixX3 for cholesterol reduction. It also provides YourBiotixBP for blood pressure reduction; and … Read more